Corcept Therapeutics (CORT) Q1 FY26 earnings call

Corcept Therapeutics delivered a strong Q1 FY26, driven by robust demand for its hypercortisolism medications and the successful early launch of Lifyorli for platinum-resistant ovarian cancer. The company raised its full-year revenue guidance, reflecting confidence in both its established endocrinology business, bolstered by recent trial findings, and the rapid adoption of its newly approved oncology drug. Significant pipeline progress across oncology, MASH, and ALS programs further underscores the company's commitment to cortisol modulation as a broad therapeutic approach.